Research Paper

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia

Alois Gratwohl\textsuperscript{a}, Rafael Duarte\textsuperscript{b}, John A. Snowden\textsuperscript{c}, Anja van Biezen\textsuperscript{d}, Helen Baldomero\textsuperscript{e}, Jane Apperley\textsuperscript{f}, Jan Cornelissen\textsuperscript{g}, Hildegard T. Greinix\textsuperscript{h}, Eoin Mc Grath\textsuperscript{i}, Mohamad Mohty\textsuperscript{j,k}, Niclaus Kroeger\textsuperscript{l}, Arnon Nagler\textsuperscript{m}, Dietger Niederwieser\textsuperscript{n}, Hein Putter\textsuperscript{d}, Ronald Brand\textsuperscript{d}, for the Joint Accreditation Committee JACIE

\textsuperscript{a}Hematology, Medical Faculty, University of Basel, Basel, Switzerland
\textsuperscript{b}Department of Hematology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
\textsuperscript{c}Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
\textsuperscript{d}Department of Biomedical Data Sciences, Section Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands
\textsuperscript{e}EBMT activity survey office, University Hospital, Basel, Switzerland
\textsuperscript{f}Centre for Haematology, Hammersmith Hospital, Imperial College London, United Kingdom
\textsuperscript{g}Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
\textsuperscript{h}Division of Hematology, Medical University of Graz, Graz, Austria
\textsuperscript{i}JACIE Accreditation Office, Barcelona, Spain
\textsuperscript{j}Hematology, Hôpital St. Antoine, Paris, France
\textsuperscript{k}Sorbonne University, Paris, France
\textsuperscript{l}Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany
\textsuperscript{m}Chaim Sheba Medical Center, Tel-Hashomer, Israel
\textsuperscript{n}Hematology and Oncology, University Hospital, Leipzig, Germany

\textbf{A R T I C L E I N F O}

\textbf{Article history:}
Received 20 May 2019
Revised 6 July 2019
Accepted 30 July 2019
Available online 9 August 2019

\textbf{Keywords:}
Haematopoietic stem cell transplantation
Acute leukaemia
Risk factors
Conditioning
Stem cell source
Benchmarking

\textbf{A B S T R A C T}

\textbf{Background:} The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in allogeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking centres.

\textbf{Methods:} This Retrospective, multicenter exploratory-validation analysis of 9103 patients, (55.5\% male, median age 50 years; 1–75 years range) with an allogeneic HSCT between 2010 and 2016 from a matched sibling (N = 8641; 95\%) or matched unrelated donor (N = 462; 5\%) for acute myeloid (N = 6432; 71\%) or acute lymphoblastic (N = 2671; 29\%) leukaemia in first complete remission, and reported by 240 centres in 30 countries to the benchmark database of the European Society for Blood and Marrow Transplantation (EBMT) searched for factors associated with use of transplant techniques (standard N = 6375; 70\% or reduced intensity N = 2728; 30\%, respectively bone marrow N = 1945; 21\% or peripheral blood N = 7158; 79\% as stem cell source), and their impact on outcome.

\textbf{Findings:} Treatment groups differed significantly from baseline population (p < 0.001), and within groups regarding patient-, disease-, donor-, and centre-related pre-transplantation risk factors (p < 0.001); choice of technique did depend on pre-transplantation risk factors and centre (p < 0.001). Probability of overall survival at 5 years decreased systematically and significantly with increasing pre-transplantation risk score (score 2 vs 0/1 HR: 1.2, 95\% c.i. [1.1–1.3], p < 0.002; score 3 vs 0/1 HR: 1.5, 95\% c.i. [1.3–1.7], p < 0.001; score 4/5/6 vs 0/1 HR: 1.9, 95\% c.i. [1.6–2.2], p < 0.001) with no significant differences between treatment groups (likelihood ratio test on interaction: p = 0.40). Overall survival was significantly associated with selection steps and completeness of information (p < 0.001).

\textbf{Interpretation:} Patients’ pre-transplantation risk factors determine survival, independent of transplant techniques. Transplant techniques should be regarded as centre policy, not stratification factor in benchmarking. Selection criteria and completeness of data bias outcome. Outcomes may be improved more effectively through better identifying pre-transplantation factors as opposed to refinement of transplant techniques.

\textbf{Funding:} The study was funded by EBMT.

© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

E-mail address: alois.gratwohl@unibas.ch (A. Gratwohl).

https://doi.org/10.1016/j.eclinm.2019.07.019

Z589-5370 © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
1. Introduction

Allogeneic haematopoietic stem cell transplantation (HSCT) provides a curative treatment for selected patients with severe congenital or acquired disorders of the haematopoietic system, but remains associated with significant morbidity and mortality, despite improvements over the last decades [1–3]. Relapse of the primary disease or death due to early or late treatment complications are the main determinants of failure [4]. A wide range of patient-, donor-, disease-, and centre-related pre-, peri-, and post-transplantation risk factors contributes to final outcome [1,3,5].

A simple score of five pre-transplantation factors was established and validated 20 years ago to predict the risk for failure, and to permit an integrated risk-adapted approach [6,7]. Patient selection, disease classification, disease treatment, donor choice and transplant techniques have since changed [2–5,8,9]. New concepts including co-morbidity index or disease risk score have been developed to better predict outcome [10]. Pilot studies, based on carefully conducted animal studies, have suggested that novel transplant technologies might mitigate against the elevated mortality for high risk patients, and open up transplantation for “elderly and frail patients” [11–13]. Pro- and retrospective studies have yielded conflicting results [14–16].

The answer is relevant for individual patients but also when transplant centres are compared for their performance. Benchmarking is now advocated to improve patient outcome [17–20]. It is used in several countries, and has been incorporated as an accreditation standard since the 6th edition of the FACT-JACIE standards [21]. The best method is not defined. The potential risk, to focus more on ranking than patient perspectives, has only recently been outlined [22].

Within the framework of an ongoing JACIE/EBMT project, we were interested to learn more about the respective roles of transplant techniques and pre-transplantation risks on final outcome, and to find out about their respective place in benchmarking. We concentrated on conditioning intensity and stem cell source. Conditioning is required to reduce rejection and disease burden; stem cells are needed to restore hematopoiesis [1–3]. Both techniques present with a Janus-face [23]. Decreased conditioning intensity might reduce early mortality but increase risk of relapse; peripheral blood as stem cell source can lead to a more rapid engraftment, but to a higher rate of chronic graft-versus-host disease (GvHD) [24]. We focused on a well-defined, homogeneous, and recent patient cohort, with the most frequent indication for allogeneic HSCT, acute leukaemia [2,8,9]. We looked for factors associated with the choice of transplant techniques and we asked whether the effect of well-known pre-transplantation risk factors would be modified by the transplant techniques. We wanted to learn whether the latter should be used as adjustment criteria for benchmarking, or regarded as part of the centre’s policy.

2. Methods

2.1. Study Design, Patient Selection and Final Patient Population

This retrospective observational analysis is an extract from the EBMT megafile (www.ebmt.org), locked at a specific time point, and kept unmodified for benchmarking questions without re-contacting centres. It holds information on 407,460 (196,175; 48% allogeneic) patients treated between 2010 and 2016 by an allogeneic HSCT for an acquired haematological malignancy, and reported by 240 teams in 30 countries (Table 1). They correspond to approximately 80% of patients with HSCT as listed in the EBMT activity survey within the same time frame [8]. We concentrated on patients (adult and paediatric) with a transplant from an HLA-identical sibling or HLA-matched unrelated bone marrow or peripheral blood stem cell donor for primary acute myeloid or lymphoblastic leukaemia in 1st complete remission (1st CR) (see Supplementary Table 1), and information on the key risk factors (see below) (Table 2) [11]. Patient survival data were updated as of January 1st, 2018. This final cohort included 6375 patients (70%) with standard, 2728 patients (30%) with reduced intensity conditioning, 1945 patients (21%) with bone marrow, 7158 (79%) with peripheral blood as stem cell source (Table 2). They represent about 10% of all allogeneic HSCT in this benchmark cohort.

2.2. Definitions

We defined acute leukaemia as primary, when “primary” was reported to the database with the main diagnosis at time of diagnosis and at time of transplant. The time intervals from diagnosis to 1stCR and from 1stCR to transplant were categorized into two groups each: ≤3 months versus >3 months [5].

Donor type was restricted to four categories depending on donor-recipient matching (matched sibling donors or matched...
unrelated donors only) and on donor and recipient sex: HLA-identical, HY + or HY - sibling, and HLA-matched, HY+ or HY- unrelated donors. HY+ refers to a female donor for a male recipient, HY- to all other donor-recipient sex combinations [23]. Conditioning intensity was used as previously defined and classified by the reporting team into standard or reduced intensity conditioning [23]. Stem cell source was restricted to bone marrow or peripheral blood; patients with cord blood or combined sources were excluded (Table 1).

All types of graft-versus-host disease (GVHD) prophylaxis were included, but ignored as factors in the analysis. Type of prophylaxis varied from centre to centre, and there is no documented superior combination regarding overall survival than a calcineurin inhibitor with or without methotrexate [9].
2.3. Statistical Analysis

This complex analysis comprised a multi-step process. First, we compared at each selection step overall survival of the included versus excluded patients (Table 1). For the final group of 9103 patients, a stratified Cox model (stratification by conditioning) was used to investigate possible non-proportionality due to differently shaped curves corresponding to conditioning intensity as reported in the literature [14–16]. The qualitative interaction (i.e. “crossing curves”) could be resolved by incorporating the significant and strong interaction between stem cell source (bone marrow versus peripheral blood), and conditioning (standard versus reduced intensity conditioning). The interaction term was then replaced by a 4-level factor of the four combinations. Conditioning and stem cell source served therefore as adjustment factors, without comparing directly the types of transplant techniques with each other. All inference on the other factors remained virtually the same and the replacement of the interaction term by a 4-level covariate did facilitate the clinical interpretation of the other hazard ratios.

We then searched for factors associated with use of transplant technique. The likelihood of patients to receive reduced intensity conditioning was estimated by a logistic regression model using calendar year, patient age, Karnofsky (adult)/Lansky (paediatric) performance score, disease and donor type. A second estimate was obtained by adding the centre identification itself and whether the time between diagnosis and 1st CR was indeed reported by the respective centre. The former was used to estimate the average likelihood for the study population of receiving a reduced intensity conditioning based on patient pre-transplantation characteristics. The latter incorporated centre characteristics, i.e. the willingness to perform a reduced intensity conditioning procedure, and the centres’ quality of reporting. In a similar approach, we estimated the likelihood of receiving peripheral blood compared to bone marrow as stem cell source.

For factors associated with outcome, the main endpoint was the probability of overall survival up to 5 years in a Cox model [10]. We used a modified EBMT pre-transplantation risk score [5]. Patient age (< 20 years, 20–40 years, 40–60 years, > 60 years: 0–3 score points), donor type (matched sibling or matched unrelated; 0–1 score points), HY status (HY– vs HY+; 0–1 score points), and Karnofsky/Lansky score (>80 versus ≤80; 0–1 score points) contributed to the final score (score 0 to maximum 6) (Table 2). As macro- and micro-economic covariates at the centre level, we used the country specific Human Development Index (www.hdi.org) and accreditation status [25]. Calendar year was included as a continuous covariate.

The analyses were first performed for the 6432 patients with acute myeloid leukaemia. Having developed the survival model, we checked that the results were valid also for the 2671 patients with acute lymphoblastic leukaemia in 1st CR separately (data not shown). After checking that no significant interaction took place between the diseases and the other covariates (Supplementary Table 1), we finally analyzed the combined data set of 9103 patients, but adjusting for disease to increase the power of the estimates.

The analyses were performed in SPSS version 25.

2.4. Organizational and Ethical Aspects

EBMT teams are required to obtain patients’ consent for data transfer to EBMT in accordance with appropriate internal approval for their transplant programs and European Data Protection Regulations (GDPR) if applicable (https://eugdpr.org/). Adherence to these requirements and accuracy of data reporting is regularly audited within the JACIE accreditation process. The data set was locked at time of transfer to the statistical office. On purpose, to reflect a benchmarking process at time x, no attempt was made nor could be made to retrieve missing data. According to the laws in the Netherlands and Switzerland, no ethics approval was mandated for this analysis with anonymized data.

3. Results

3.1. Selection Process

The benchmark file population was reduced in 9 steps from the initial 407,460 patients to the final 9103. This process showed a systematic and significant change in overall survival at 5 years at each step of the selection process, with one exception. Results confirmed the well-known roles of year of transplant, main donor type, main disease category, cord blood as stem cell source, primary versus secondary leukaemia, and remission status (all $p < 0.001$) (Table 1). As a novel finding, we identified a significantly worse overall survival for patients with missing information (HR: 0.88; 0.83–94) ($p < 0.001$), and a significant correlation between missing information, accreditation status and the age of the patients. Patients with incomplete information were more likely to be reported from non-accredited centres ($p < 0.001$) and younger ($p < 0.001$), with a higher proportion of paediatric patients in non-accredited (18.4%) than accredited centres (10.2%). However, the proportion of patients with incomplete information was 20% for paediatric patients in both, accredited and non-accredited centres; it was 11.2% for adult patients in non-accredited, 5.5% in accredited centres (Supplementary Table 2a).

Information on the degree of matching (matched or mismatched) was missing in a much higher proportion of unrelated donor than sibling donor transplants (Table 1; step 8), leading to an under representative proportion of unrelated HSCT of only 5%.

3.2. Patient Population

There were significant differences between patients with acute myeloid and acute lymphoblastic leukaemia, between patients with standard or reduced intensity conditioning, and between patients with or without a known time interval from diagnosis to 1st CR (Table 2). Patients with primary acute lymphoblastic leukaemia were more likely to be males (60.2% vs 53.5%; $p < 0.001$), were younger (59.6% < 40 years old vs 31.9%; $p < 0.001$), had lower Karnofsky/Lansky scores (18.1% < 80 vs 15.7%; $p = 0.005$), and had a lower pre-transplantation scores (76.4% score 0–2 vs 60.8%; test for trend $p = 0.001$). Patients with reduced intensity conditioning were more likely to have acute myeloid leukaemia, 83% vs 66%; $p < 0.001$, were older (39.8% > 60 years old vs 51%; $p < 0.001$), showed a higher proportion with low performance score (22.2% ≥ 80 vs 14%; $p < 0.001$), were preferentially given peripheral blood as stem cell source (92% vs 73%; $p < 0.001$) and had a higher proportion of unrelated donor transplants (6.5% vs 4.5%; $p = 0.001$) (Table 2).

Patients with information on time sub-intervals (time from diagnosis to 1st CR and time from 1st CR to transplant; N = 2586) were more likely to be reported from accredited than non-accredited centres (42.0% vs 17.2%; $p < 0.001$), and to have a lower proportion of patients with a low pre-score of 0–2 (56.9% vs 68.8%; $p < 0.001$) (Supplementary Table 2b). Overall survival of patients with full information, in contrast, was not different. Hence, centres with missing information had a higher proportion of lower risk patients.

3.3. Factors Associated With Transplant Practice

The analysis showed no apparent consistency in the choice of conditioning regimen across transplant centres, even when patients showed the same pre-transplantation characteristics (Supplementary Fig. 1a). The same applied to the likelihood of receiving peripheral blood compared to bone marrow as stem cell source (Supplementary Fig. 1b). Age ($p < 0.001$), Karnofsky’s score...
Fig. 1. Factors associated with choice of transplant technique for 9103 patients with a haematopoietic stem cell transplant for primary acute myeloid or acute lymphoblastic leukaemia in 1st complete remission.

The graphs illustrate the probability of choice without (x-axis) and with (y-axis) considering transplant centre (CIC = Centre identification code of transplanting team) as factor.

Each dot represents one patient. For details, see Methods section.

a: Choice of reduced intensity conditioning (RIC).
   Top: AML (= acute myeloid leukaemia); Bottom: ALL (= acute lymphoblastic leukaemia).
   R-square: 0.51 (top) and 0.46 (bottom).

b: Choice of peripheral blood as stem cell source, by patients’ characteristics and conditioning.
   Top: AML; Bottom: ALL; Left: standard conditioning; Right: reduced intensity conditioning.
   R-square: 0.22 (top left), 0.13 (top right), 0.27 (bottom left), 0.24 (bottom right).
A. Gratwohl, R. Duarte and J.A. Snowden et al./EClinicalMedicine 15 (2019) 33–41

Continued

Fig. 1. Continued

(p = 0.001), disease (p < 0.001) and centre (fixed factor, p < 0.001) were highly significant in a logistic regression model for choice of conditioning, while donor type (p = 0.80) and calendar year (p = 0.12) were not. For the choice of type of stem cells, calendar time (p = 0.001), age (p < 0.001), Karnofsky’s score (p = 0.01), donor type (p = 0.017), conditioning (p < 0.001) and centre (fixed factor, p < 0.001) were highly significant, while disease was not. The apparent arbitrariness, in terms of patient characteristics, to decide for or against a given transplant technology is reflected by the scattergram when the likelihood was calculated with or without centre identification code as a fixed factor in the model (Fig. 1aa and b).

3.4. “Standard” Risk Factors and Univariate Outcome

Probability of overall survival at 5 years was 59% for patients with primary acute lymphoblastic leukaemia, 55% for patients with primary acute myeloid leukaemia (Fig. 2a). The survival pattern showed no indication for a ‘Janus face’ of conditioning intensity and stem cell source. Early overall survival at day 30 was 99% for the whole group. The analysis confirmed previously defined risk factors with a similar pattern for the four subgroups. Overall survival decreased systematically with increasing recipient age from 64% at 5 years for the <20 years old to 48% for the >60 years old patients (p < 0.001) (Supplementary Fig. 2a), and with increasing histoincompatibility (p < 0.001) (Supplementary Fig. 2b). Patients with a Karnofsky/Lansky score > 80 showed an overall survival of 58% at 5 years compared to 49% for those with a score of 80 or lower (p < 0.001) (Supplementary Fig. 2c). Combined in a score as summarized above, overall survival decreased stepwise from close to 80% at 5 years with score 0; 58% with score 2; 50% with score 3, to 45% with score 4 to less than 40% with scores 5 and 6 (p < 0.001) (Supplementary Fig. 2d).

3.5. Multivariate Effects of Pre-existing and Treatment-related Risk Factors on Outcome

Overall survival decreased in a risk adjusted Cox model systematically, significantly and stepwise with increasing pre-transplant risk score in a four group analysis: (score 2 vs 0/1 HR: 1.2, 95% c.i. [1.1–1.3], p = 0.002; score 3 vs 0/1 HR: 1.5, 95% c.i. [1.3–1.7], p < 0.001; score 4/5/6 vs 0/1 HR: 1.9, 95% c.i. [1.6–2.2], p < 0.001), whether source of stem cells and conditioning were included in the model together with their interaction or as stratification factors to allow for non-proportionality. There was no indication at all that conditioning or source would alter the inherent pre-transplantation risk (likelihood ratio test on interaction: p = 0.40) (Fig. 2b; Table 3).

The same effect was observed, with obvious loss of power, when the four groups of conditioning and stem cell source were analyzed independently. There was one exception in the small group of patients (N = 224) with reduced intensity conditioning and bone marrow as source (Supplementary Table 3).

The analysis was not designed to compare the four groups of conditioning and stem cell source. With all limitations, when
Fig. 2. Probability of overall survival of 9103 patients with a haematopoietic stem cell transplant for primary acute myeloid or acute lymphoblastic leukaemia in 1st complete remission during the years 2010 to 2016.

a: Overall survival for the whole group, by main disease. AML = acute myeloid leukaemia; ALL = acute lymphoblastic leukaemia.
b: Overall survival by pre-transplant-risk score. The curves represent probability of overall survival, as evaluated for a patient with a haematopoietic stem cell transplant for acute myeloid leukaemia in 1st complete remission in 2010, in an accredited centre in a country with the highest tertile for Human Development Index, using standard conditioning and peripheral blood as stem cell source. The survival curves are multivariately adjusted for accreditation, calendar year, Human Development Index, conditioning and source of stem cells. Pre-transplant scores are divided by scores 0/1, 2, 3, 4/5/6 (for details, see Methods section).

acute myeloid leukaemia and acute lymphoblastic leukaemia patients were analyzed separately, the analysis showed no significant differences between the four groups for patients with acute myeloid leukaemia. It indicated significant differences for patients with acute lymphoblastic leukaemia, and best survival for patients with standard conditioning and bone marrow as source (Table 3).

3.6. Additional Factors

The multivariate analysis confirmed a better overall survival in accredited centres (HR: 0.886, 95% c.i. [0.814–0.965], p = 0.005), and a decrease of overall survival over calendar years time (HR: 1.031, 95% c.i. [1.007–1.055], p = 0.010, per year). It confirmed the lower probability of overall survival for patients with a longer time interval from diagnosis to 1st CR (p < 0.001), possibly reflecting the need for additional chemotherapy to achieve remission [5]. The effect was more pronounced in patients with acute lymphoblastic leukaemia (Supplementary Fig. 3). As previously described, the total time from diagnosis to transplant, not considering the subintervals, had no effect on outcome [5].

4. Discussion

This retrospective cohort analysis provided clear answers regarding both, factors associated with choice of transplant technique, and factors associated with outcome. As shown in this
Factors associated with probability of overall survival. Data present the risk of mortality (Hazard ratios; HR, with 95% confidence intervals) for 9103 patients with a haematopoietic stem cell transplant for acute leukaemia (acute myeloid leukaemia:6432; acute lymphoblastic leukaemia:2671) in 1st complete remission, depending on pre-transplant risk factors (pre-score), centre's macro- and micro-economic factors, and choice of transplant technique. The model allowed for any interaction of the disease with the other risk factors.

| Sig. | HR | 95.0% CI for Exp(B) |
|------|----|---------------------|
| Pre-score (0/1) |    |                     |
| 2    | 0.02 | 1.187 1.063 1.326   |
| 3    | 0.00 | 1.490 1.318 1.684   |
| 4/5  | 0.00 | 1.902 1.634 2.215   |
| Accredited by 2012 | 0.005 | 0.886 0.814 0.965 |
| Percentile group of HDI (high vs other) | 0.380 | 1.041 0.952 1.139 |
| Year of treatment (per year) | 0.010 | 1.031 1.007 1.055 |
| Evaluation for AML |   |                     |
| MAC+BM (ref cat) | 1.0 |                     |
| MAC+PB | 0.436 | 1.059 0.917 1.221 |
| RIC+BM | 0.978 | 1.004 0.743 1.358 |
| RIC+PB | 0.966 | 0.997 0.850 1.168 |
| Evaluation for ALL |   |                     |
| MAC+BM (ref cat) | 1.0 |                     |
| MAC+PB | 0.901 | 1.410 1.156 1.720 |
| RIC+BM | 2.072 | 1.486 0.803 2.748 |
| RIC+PB | 0.000 | 1.775 1.389 2.270 |

- Adding interactions with disease was necessary to obtain a good proportional hazards model fit analyzing both diseases together (to increase the power for the estimates of the patient-related effects).
- All interactions between disease and the risk factors were non-significant except for the effect of conditioning and source of stem cells being modified by the disease (p<0.001). The dose-response effect of the Pre-score may be assumed to be the same in AML and ALL.
- When estimating the same model separately among AML resp. ALL, the HRs were almost identical to the averaged effects in this table.
- No interpretation of the differing HR's for conditioning and source of stem cells between AML and ALL are attempted since the very definition of RIC could be different among AML and ALL and varying over calendar time and centres. Conditioning is merely used as a covariate to remove bias in the estimates of the pre-score and other patient related factors due to a possible correlation with conditioning and/or source of stem cells.
- MAC: myeloablative conditioning – reduced intensity conditioning; RIC: reduced-intensity conditioning. For definitions, see Methods.
- Sig: p value; BM: bone marrow; PB: peripheral blood.
- HDI: Human Development Index.

Large homogeneous patient population, centre preference and large and pre-transplantation patients' characteristics determined the choice of transplant techniques, e.g. conditioning intensity and stem cell source. Pre-transplantation properties were predictive for overall survival. Overall survival at 5 years decreased systematically and stepwise from close to 80% to less than 40%, all in patients with acute leukaemia in 1st CR. No preferential type of conditioning changed this pattern or reduced mortality for patients with high pre-transplantation risk scores [13–16]. In addition, the study revealed a significant impact of the selection process, and a significantly worse overall survival for patients with incomplete information. These are novel findings, with direct consequences regarding benchmarking.

Benchmarking aims to improve the quality of patient care and outcomes [17–20]. Its success depends on widespread perception of ‘fairness’ through risk-adjustment for differences in patient population characteristics. Withholding known information, intentionally or not, can introduce bias. As shown in this study, completeness of information on known pre-transplantation risk factors appears to be essential for proper risk-adaptation. There is a scarcity of published information about variations between centres in quantity and quality of patient data reporting. The standards of the JACIE accreditation process aim to assure quality in this respect. Thus, the concept of ‘fairness’ becomes a mutual responsibility between a centre and the benchmarking system.

The analysis revealed additional novel elements. We found no signs of a ‘janus-face’ effect of the transplant techniques [23]. The excellent day 100 survival precludes any early comparison. Regarding late survival, some patients with acute leukaemia in 1st complete remission are cured before the transplant, independent of conditioning [7]. Second, about one third of patients with matched donors never ever develop any graft-versus-host disease [26]. There is no tool yet available to identify such patients before the transplant.

Major caveats remain. There were significant differences between the groups which could not be adjusted for. We did not include methods of graft-versus-host disease prevention, or the “post-transplant cyclophosphamide” concept [8,9]. Information on “matching” of donor and recipient was too frequently missing, especially in unrelated donor transplants, leading to a too low number of unrelated HSCT compared to current practice [8,9]. This practice might reflect a general problem of the database. “Matched” as indicated by the reporting team, and used in the analysis, is still ill defined and might range from an 8/8 HLA-antigen to a 12/12 HLA-allelic match or beyond [9]. Transplant organizations are challenged to better define categories and to improve reporting.

Performance scores may fail to accommodate co-morbidities or the complex frailty of older patients [27]. Molecular, cytogenetic, and minimal residual disease status was not available, information which is especially relevant for individual decision-making [7]. Still, no attempt was made to retrieve additional data in order to reflect a status quo at any time of a benchmarking process. The large numbers and the complexity of the findings provide sufficient validity to the report.

The results provide guidance for future benchmarking strategies. Wide variations in infrastructure and use of transplant techniques are well described [4,8,9]: it may be challenging to incorporate the impact of these variations. Reassuringly and based on our results, transplant techniques should be considered a centre-specific (“policy”) property rather than to be used as adjustment factor. In addition, “completeness of data reporting” almost becomes a surrogate marker for quality of transplant outcome.

In the current era of personalized medicine, HSCT has to provide a better outcome regarding overall survival, quality of life and costs. To achieve this goal, risks and benefits of HSCT have to be balanced continuously from diagnosis on with those of a non-transplant strategy [28]. Decisions should then be based on defined data, collected and analyzed according to the WHO principles [5,7,8,29].

Hence, assessing transplant centre quality through any accreditation or ‘benchmarking’ system should concentrate on completeness of data reporting, must define any selection beforehand, and must strive to include non-transplanted patients as well. The analysis also supports the hypothesis that transplant outcomes may be improved more effectively through identifying hitherto ‘hidden’ pre-transplantation factors as opposed to refinement of transplant techniques.

The implications of this report may apply to other disease categories as well, to other cellular treatment approaches, or when developing novel machine learning tools [30].

**Acknowledgements**

The authors acknowledge the cooperation of the participating teams and their staff: the JACIE Accreditation Office in Barcelona, the JACIE Board and Executive Committee, the JACIE Medical Directors, the JACIE Accreditation Committee, all JACIE inspectors and EBMT registered transplant programs; the EBMT presidents and the working party chairs; the EBMT statistical office in Leiden; the EBMT Co-ordination offices in Barcelona, Paris and London, the
Austrian Registry (ASCTR), the Czech BMT Registry, the French Registry (SFCM-TC), the German Registry (DRST), the Italian Registry (GITMO), the Dutch Registry (HOVON), the Spanish BMT Registry (GETH), the Swiss Registry (SBST), the Turkish BMT Registry and the British Registry (BSBMT). The funders had no role in study design, data collection, data analysis, interpretation, writing of the report.

Funding

The study was funded by the European Group for Blood and Marrow Transplantation EBMT, by the Joint Accreditation Committee of EBMT and ISHAGE-Europe JACIE, and the European Leukemia Net ELN. EBMT is supported by grants from the corporate members: Amgen Europe, ViroPharma Europe, Celgene International SARL, Genzyme Europe B.V., Gilead Sciences Europe Ltd., MiltenyiBiotec GmbH, Schering-Plough International Inc., Bristol Myers Squibb, CaridiaBCT Europe NV, Cephalon Europe, F. Hoffmann-La Roche Ltd., Fresenius Biotech GmbH, Therakos Inc., Alexion Europe, Chugai Sanofi – Aventis, Merck Sharp and Dohme, Novartis, Pfizer, Pierre Fabre Médicament.

Declaration of Competing Interest

RD, and JS initiated the study for the JACIE benchmarking project. AG and RB designed the study concept and drafted the manuscript. RB and HP conducted the statistical analysis. DN and JC were responsible for discussion of concept and critical reviewing of data. AvB, EMTG and HB were responsible for the data organization. JA, JC, HTG, MM, NK, AN, and DN were responsible for the data collection and data interpretation within their working parties and for advice. All authors have contributed to the writing, have seen the last version, and have approved of it. Writing of the manuscript was the sole responsibility of the authors. Dr. Gratwohl reports consulting fees from Takeda outside the submitted work. Dr. Duarte reports grants, personal fees and non-financial support from Merck Sharp and Dohme, personal fees and non-financial support from Jazz Pharmaceuticals, personal fees and non-financial support from Biogen, personal fees from Omeros and non-financial support from the American Society for Blood and Marrow Transplantation. Dr. Mohty reports personal fees from Janssen, Celgene, Amgen, Therakos, Novartis, Cellgene, MSD, Sanofi, outside the submitted work. Dr. Mohty reports personal fees from Janssen, Celgene, Amgen, BMS, Sanofi, Jazz, Takeda, Adaptive Biotechnologies, and grants from Sanofi, Janssen, Jazz, Roche, BMS outside the submitted work. Dr. Snowden reports personal fees from Janssen, Jazz, Kiadis, NHS ENGLAND, and MALLINCKRODT outside the submitted work. Dr. Niedierwieser reports grants from Novartis, non-financial support from Amgen, other from Cellectis, other from Bayer, outside the submitted work; and support from the project “Zusammen gegen Krebs”. All other authors have no conflicts of interest to declare.

Appendix A. Supplementary Data

Supplementary data to this article can be found at https://doi.org/10.1016/j.eclinm.2019.07.019.

References

[1] Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–26.

[2] Gratwohl A, Baldomero H, Aljurf M, Worldwide Network of Blood and Marrow Transplantation, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617–24.

[3] Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–101.

[4] Styczynski J, Tridelco G, Koster L, et al. For the Infectious Diseases Working Party EBMT Death after hematopoietic stem cell transplantation: associated factors, infections, and changes over calendar year time. Bone Marrow Transplant 2019;54:i57–66.

[5] Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012;47:749–56.

[6] Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087–92.

[7] Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9:579–90.

[8] Passweg JR, Baldomero H, Bader P, European Society for Blood and Marrow Transplantation (EBMT), et al. Is the use of unrelated donor transplantation leading off in Europe? European Society for Blood and Marrow Transplantation Activity survey report. Bone Marrow Transplant 2018;53:1139–48.

[9] Duarte RF, Labopin M, Bader P, European Society for Blood and Marrow Transplantation (EBMT), et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe. 2019. Bone Marrow Transplant 2019. doi:10.1038/s41409-019-0516-2.

[10] Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664–71.

[11] Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048–54.

[12] Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppressive pretreatment with cyclosporine and mycophenolate mofetil in patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RIMCAML trial). J Clin Oncol 2017;35:2157–64.

[13] Scott BL, Pasquini MC, Logan BR, et al. Myeloblastic versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017;35:1154–61.

[14] Snowden JA, McGrath E, Duarte RF, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant 2017;52:1367–71.

[15] https://unios.org/solutions/research-data-analytics/.

[16] Logan BR, Nelson GO, Klein JF, Analyzing center specific outcomes in hematopoietic cell transplantation. Blood Cancer J 2016;6:48.

[17] Health Resources & Services Administration. https://bloodcelltransplant.hrsa.gov/index.html. Assessed May 3, 2019.

[18] https://www.factweb.org/forms/Imag/order/ProductFormPublicSixth-edition-fact-juice-international-standards-for-hematopoietic-cellular-therapy-producing-collection-processing-and-administration-free-download. Assessed May 3, 2019.

[19] Lamas DJ, Lakin JR, Trindade AJ, Courtwright A, Goldberg H. Looking beyond mortality in transplantation outcomes. N Engl J Med 2018;379:1889–91.

[20] Gratwohl A, Sureda A, Cornelissen J, et al. Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. Leukemia 2017;31:1752–9.

[21] Holtick U, Albrecht M, Chemnitz JM, et al. Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015;94:179–88.

[22] Gratwohl A, Sureda A, Baldomero H, Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) and the European Leukemia Net (ELN), et al. Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine 2015;2:2101–9.

[23] Gratwohl A, Ruiz de Elvira C, Gratwohl M, Greinix HT, Duarte R, Grant-versus-Host Disease Subcommittee of the Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Gender and graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016;22:1145–6.

[24] Hegde A, Murthy HS. Frailty: the missing piece of the pre- hematopoietic stem cell transplantation assessment? Bone Marrow Transplant 2018;53:3–10.

[25] Klimova TM, Rudivi F, Cortes J, Kantarjian H. Toward individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol 2015;1:820–8.

[26] World Health Organization, WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010;90:229–33.

[27] Rajkomar A, Dean J, Kohane I. New Engl J Med 2019;380:1347–58.